Jing Wang

Ph.D.

Senior Scientist, Regenerative Medicine

Ottawa Hospital Research Institute

Associate Professor, Department of Cellular and Molecular Medicine

University of Ottawa

Contact

613-7378899 ext 71954

Bio

Dr. Jing Wang received her Bachelor of Medicine in China and then came to Canada for her graduate studies. She obtained her M.Sc. in Physiology at McGill University and her Ph.D. in Biochemistry from the University of Ottawa. Subsequently, she completed her post-doctoral training with Dr. Freda Miller at the Hospital for Sick Children in Toronto and then joined OHRI as a scientist and assistant professor at the University of Ottawa. Her research program focuses on understanding the molecular mechanisms that regulate neural stem cell reprogramming and differentiation in the context of neurodevelopmental and neurodegenerative diseases (ASD, Alzheimer's disease, Stroke and Multiple Sclerosis) with the goal of identifying potential regenerative therapeutic approaches to treat these devastating neurological diseases.

Research Goals and Interests

The discovery of adult neural stem cells residing in the mammalian brain holds great promise for treating devastating neurodegenerative diseases such as Stroke, and Alzheimer's Disease. The main focus of the laboratory research is delineating molecular mechanisms that regulate neural stem cell reprogramming and differentiation, with the ultimate goal of defining ways to recruit the stem cells to thereby potentially promote neural repair. A variety of molecular, cellular, and behavioral techniques are used in the laboratory to elucidate novel molecular pathways that regulate neural stem cell behaviors, including transgenic mouse models, neurosphere culture, and in vivo viral-mediated gene delivery approach. 

Dr. Wang's research program focuses on dissecting the molecular mechanisms that regulate neural stem cell reprogramming and differentiation in the context of neurological diseases including Alzheimer's Disease, Stroke and Multiple Sclerosis, and further using this understanding to rationally design and test therapies for neural injury and degeneration.  Several ongoing research projects are described below.

1. Molecular control of lipid metabolism in brain aging: We have identified the role of atypical protein kinase C (aPKC) mediated Ser 436 phosphorylation in CBP, a histone acetyltransferase (HAT), as an important mechanism that sustains hippocampal neuronal differentiation, maturation, and memory during normal aging (Stem Cell Reports, 2016). We also demonstrate that metformin, an FDA-approved anti-diabetic drug, can activate the aPKC-CBP pathway to promote NPC neuronal differentiation and improve hippocampus-associated memory in vivo (Stem Cell Reports, 2015, Cell Stem Cell, 2012). Our recent publication (Theronostics, 2020) reveals that when the aPKC-CBP pathway is impaired in an AD animal model during pathological aging, monoacylglycerol lipase (Mgll) levels are highly upregulated in hippocampi to reduce neuronal differentiation and impair spatial memory in the AD animal model. Intriguingly,  these AD-associated deficits can be rescued by metformin treatment through reactivating the aPKC-CBP mediated Mgll gene repression. Ongoing research program continue to identify extrinsic source of Mgll and its roles in regulating neural stem cell behavior in vivo and aim to translate the findings into clinical applications. 
Technical diagram of molecular control of lipid metabolism in brain aging
2.Optimizing cell-based therapies to promote neurovascular regeneration and behavioural recovery after ischemic stroke. We recently used a rat Endothelin-1 (ET-1) focal ischemic stroke model  to demonstrate that preconditioning of human iPSC derived neural stem cells (hiPSC-NSCs) with metformin before transplantation into the stroke-damaged brains improves engraftment and regeneration capabilities of hiPSC-NSCs and ultimately accelerates gross motor recovery and reduces infarct volume (Stem cells and Development, 2018). Ongoing research project continues to optimize cell-based therapies to promote neurovascular regeneration and behavioural recovery following ischemic stroke.
   
Diagram of naive cells and metformin cells and graphs of proliferation and differentiation
3. Targeting in vivo cellular reprogramming for post-stroke neural regeneration and recovery. We used a mouse Endothelin-1 (ET-1) focal ischemic stroke model  to identify a transient population of locally-derived NSCs (i-NSCs) that are reprogrammed from pericytes in the injury site shortly after stroke.  We further show that the permanent deletion of the aPKC-CBP pathway enhances the pericyte reprogramming efficiency to multipotent NSCs, consequently exhausting proliferative pericytes and compromising the vascular remodeling to impair post-stroke functional recovery (Stem Cell Reports, 2017). In our recent published paper (Theranostics, 2024), we revealed that two distinct subtypes of pericytes possess different reprogramming potencies in response to physical and ischemic injuries using single cell RNA-seq combined with immunohistochemistry. We also developed a genomic integration-free methodology to reprogram human pericytes into functional neurons by targeting NG2+ pericytes in the dish. Current ongoing research project is to define ways to not only enhance neural reprogramming of ischemia-activated pericytes into i-neurons, but also reduce post-stroke hostile microenvironment for maximizing post-stroke local neurogenesis.

Diagram of targeting in vivo cellular reprogramming for post-stroke neural regeneration and recoveryIn vivo pericytes tracing
 This image is a scientific diagram illustrating the cellular responses in the brain under different conditions




 

Currently, we have openings for graduate student (MSc or PhD) and post-doc positions.  
Individuals who are interested in the positions should submit curriculum vitae, a copy of official transcripts, statement of research interest and names of three references to jiwang@ohri.ca.


News


Publications

Aldehydic load as an objective imaging biomarker of mild traumatic brain injury

2025-06-26 Go to publication

Single-cell profiling of brain pericyte heterogeneity following ischemic stroke unveils distinct pericyte subtype-targeted neural reprogramming potential and its underlying mechanisms

2024-09-23 Go to publication

Promising use of metformin in treating neurological disorders: biomarker-guided therapies.

2024-05-01 Go to publication

Assessing multimodal emotion recognition in multiple sclerosis with a clinically accessible measure.

2024-04-01 Go to publication

Early postnatal defects in neurogenesis in the 3xTg mouse model of Alzheimer's disease.

2023-02-18 Go to publication



2023/4 - 2028/3 NSERC DG grant (PI) Neuronal regulation of subventricular zone adult neural stem cell function and olfactory bulb neurogenesis.

2024/10-2029/9 CIHR project grant (PI) Prenatal exposure of low-dose methylmercury causes abnormal neurodevelopment and its underlying mechanisms

2025/07-2028/06 HSF Grant-in-aid (PI) Ischemia-induced pericyte neural reprogramming and it role in post stroke regeneration and functional recovery.

2025/10-2030/10 CIHR project grant (PI) Monoacylglycerol lipase (Mgll)-regulated 2-AG/eCBR signaling in feeding circuits controls adult neurogenesis

 

Related Research at The Ottawa Hospital